BIIB092 for Early Alzheimer's Disease (TANGO)

What Is This Study About?

The study will evaluate BIIB092, a monoclonal antibody, in people with mild cognitive impairment (MCI) due to Alzheimer's disease or mild Alzheimer's disease.

Do I Qualify To Participate in This Study?

Must have:

• Gradual, progressive change in memory function during more than 6 months
• MCI due to Alzheimer's disease or mild Alzheimer's disease
• Objective evidence of cognitive impairment, as shown by Clinical Dementia Rating (CDR) Scale score of 0.5 for MCI or 0.5 or 1 for mild Alzheimer's, Mini-Mental State Examination score of 22-30 (inclusive), and CDR Memory Box score of  0.5
• Consent to apolipoprotein E (ApoE) genotyping
• Informant/study partner
• Beta-amyloid positivity confirmed at screening

Must NOT have:

• Any medical or neurological/neurodegenerative condition other than Alzheimer's 
• Clinically significant, unstable psychiatric illness
• Stroke, mini-stroke, or unexplained loss of consciousness during the past year
• Brain hemorrhage, bleeding disorder, or cerebrovascular abnormalities
• History of unstable angina, heart attack, chronic heart failure, or clinically significant conduction abnormalities during the past year
• Impaired renal or liver function
• Alcohol or substance abuse during the past year
• Significant illness or infection during the past year
• Unstable medication dosing for chronic conditions during the past 4 weeks
• Unstable medication dosing for Alzheimer's disease during the past 8 weeks
• Any medication use that may contribute to cognitive impairment or increase risk for adverse events

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 

Where Is This Study Located?

Who Sponsors This Study?

Lead: Biogen

Source: ClinicalTrials.gov ID: NCT03352557